HTD1801 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 94 | 原発性硬化性胆管炎 | 3 |
94. 原発性硬化性胆管炎
臨床試験数 : 142 / 薬物数 : 113 - (DrugBank : 37) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03678480 (ClinicalTrials.gov) | March 1, 2021 | 18/9/2018 | A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC) | A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis;Cholangitis;Cholangitis, Sclerosing;Bile Duct Diseases;Biliary Tract Diseases;Digestive System Diseases;Adolescent | Drug: HTD1801;Drug: Ursodeoxycholic Acid | HighTide Biopharma Pty Ltd | NULL | Withdrawn | 12 Years | 17 Years | All | 0 | Phase 2 | NULL |
| 2 | NCT03333928 (ClinicalTrials.gov) | February 9, 2018 | 27/10/2017 | A POC and Dose-Ranging Study of HTD1801 in PSC Patients | A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis (PSC) | Drug: HTD1801;Drug: Placebo | HighTide Biopharma Pty Ltd | NULL | Completed | 18 Years | 75 Years | All | 59 | Phase 2 | United States;Canada |
| 3 | NCT03099603 (ClinicalTrials.gov) | March 24, 2017 | 14/3/2017 | A Study of HTD1801 in Healthy Subjects | A First in Human, Randomized, Double-Blind Study to Assess Safety, Tolerability, and Pharmacokinetics of Single, Ascending Doses of HTD1801 in Healthy Subjects | Primary Sclerosing Cholangitis | Drug: HTD1801 | HighTide Biopharma Pty Ltd | NULL | Completed | 18 Years | 50 Years | All | 32 | Phase 1 | Australia |